Table 3.

Other secondary end points

End point	Mavrilimumab* (N=42)	Placebo (N=28)	P value
Time to elevated erythrocyte sedimentation rate by week 26,† median (95% CI) weeks‡	26.1 (16.1, NE)	12.1 (8.1, 16.6)	0.028§
Time to elevated C reactive protein level by week 26,¶ median (95% CI) weeks‡	NE (8.1, NE)	12.3 (3.3, 24.1)	0.038§
Time to signs and symptoms of giant-cell arteritis or new or worsening vasculitis by imaging by week 26, median (95% CI) weeks‡	NE (NE, NE)	25.1 (15.1, NE)	0.065§
Cumulative prednisone dose at week 26, mean (SD) mg	2074 (708)	2403 (1014)	0.067**
Percentage of patients completing glucocorticoid taper†† and with normal erythrocyte sedimentation rate by week 26	19 (45.2%)	4 (14.3%)	0.020**
Percentage of patients completing glucocorticoid taper†† and with normal C reactive protein level by week 26	10 (23.8%)	4 (14.3%)	0.55**
Percentage of patients completing glucocorticoid taper†† and with no signs or symptoms of giant-cell arteritis by week 26	30 (71.4%)	9 (32.1%)	0.0031**
Cumulative prednisone dose at week 38‡‡, mean (SD) mg	2465 (1107)	2845 (1320)	0.16**

Data are n (%) except as indicated.

*150 mg subcutaneously every 2 weeks.

†Elevated erythrocyte sedimentation rate is defined as the first rate greater than or equal to 30 mm/hour; patients with an elevated rate within 3 days of the first dose of study drug were excluded from the analysis.

‡Kaplan-Meier method.

§Log-rank test stratified by randomisation strata.

¶Elevated C reactive protein level is defined as the first level greater than or equal to 1.0 mg/dL; patients with an elevated level within 3 days of the first dose were excluded from the analysis.

**Analysed by Cochran-Mantel-Haenszel test stratified by randomisation strata. Nominal p value.

††Patients were considered to have completed glucocorticoid taper if by week 26 they were receiving 1 mg/day for patients who had a starting dose of 60 mg/day, or 0 mg/day for patients who had a starting dose of less than 60 mg/day.

‡‡After the 26-week treatment period, investigators could manage disease in patients at their discretion, including use of glucocorticoids.